Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/asheducation-2014.1.52 http://scihub22266oqcxt.onion/10.1182/asheducation-2014.1.52 C4364029!4364029!25696834     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hematology+Am+Soc+Hematol+Educ+Program 2014 ; 2014 (1): 52-9 Nephropedia Template TP {{tp|p=25696834|t=2014. Future prospects for contact factors as therapeutic targets |pdf=|usr=}}{{25696834}} gab.com Text Future prospects for contact factors as therapeutic targets JO: Hematology Am Soc Hematol Educ Program http://www.kidney.de/pget.php?&tw=1&pmid=25696834 #FOAvip Anticoagulants currently used in clinical practice to treat or prevent thromboembolic disease are effective, but place patients at increased risk for serious bleeding because they interfere with plasma enzymes (thrombin and factor Xa) that are essential for hemostasis. In the past 10 years, work with genetically altered mice and studies in baboons and rabbits have demonstrated that the plasma contact proteases factor XI, factor XII, and prekallikrein contribute to the formation of occlusive thrombi despite having limited roles in hemostasis. In the case of factor XI, epidemiologic data from human populations indicate that elevated levels of this protein increase risk for stroke and venous thromboembolism and may also influence risk for myocardial infarction. These findings suggest that inhibiting contact activation may produce an antithrombotic effect without significantly compromising hemostasis. This chapter reviews strategies that are being developed for therapeutic targeting of factor XI and factor XII and their performances in preclinical and early human trials. Twit Text FOAVip Future prospects for contact factors as therapeutic targets ????Hematology Am Soc Hematol Educ Program http://www.kidney.de/pget.php?&tw=1&pmid=25696834 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25696834 #FOAvip English Wikipedia <ref>{{Cite pmid|25696834}}</ref> Future prospects for contact factors as therapeutic targets #MMPMID25696834 Gailani D Hematology Am Soc Hematol Educ Program 2014[Dec]; 2014 (1): 52-9 PMID25696834show ga Anticoagulants currently used in clinical practice to treat or prevent thromboembolic disease are effective, but place patients at increased risk for serious bleeding because they interfere with plasma enzymes (thrombin and factor Xa) that are essential for hemostasis. In the past 10 years, work with genetically altered mice and studies in baboons and rabbits have demonstrated that the plasma contact proteases factor XI, factor XII, and prekallikrein contribute to the formation of occlusive thrombi despite having limited roles in hemostasis. In the case of factor XI, epidemiologic data from human populations indicate that elevated levels of this protein increase risk for stroke and venous thromboembolism and may also influence risk for myocardial infarction. These findings suggest that inhibiting contact activation may produce an antithrombotic effect without significantly compromising hemostasis. This chapter reviews strategies that are being developed for therapeutic targeting of factor XI and factor XII and their performances in preclinical and early human trials. äFuture prospects for contact factors as therapeutic targets (epmc).pdf DeepDyve Pubget Overpricing